Long-term outcome in PSC/AIH "overlap syndrome": Does immunosuppression also treat the PSC component?

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 1189-1191

  Zenouzi, Roman ^a   Lohse, Ansgar W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; PREDNISOLONE; SMOOTH MUSCLE ANTIBODY; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; BILIARY CIRRHOSIS; CHOLANGITIS; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ESOPHAGUS VARICES; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; LABORATORY TEST; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; ULCERATIVE COLITIS; ADULT; CASE REPORT; CHOLANGITIS, SCLEROSING; COMPLICATION; FOLLOW UP; HEPATITIS, AUTOIMMUNE; MALE; MIDDLE AGED; SYNDROME; TREATMENT OUTCOME;

ADULT; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SYNDROME; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84932147775     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.002     Document Type: Letter

References (10)

1. Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24: 699-705.
2. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 1992;37: 1606-1611.
3. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18: 998-1005.
4. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54: 374-385.
5. Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23: 1369-1376.
6. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100: 1516-1522.
7. Luth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, et al. Characteristics and long-Term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009;43: 75-80.
8. van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33: 543-548.
9. Cullen SN, Chapman RW. Review article: Current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;21: 933-948.
10. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131: 943-946.